DaVita Inc

DVA: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$735.00LbnfrwvNqwqlygpt

DaVita Earnings: Higher Revenue Per Treatment Helps Boost 2024 Outlook and Fair Value

Narrow-moat DaVita turned in solid second-quarter results, and management bumped up its bottom-line expectations slightly. To reflect those mildly higher near-term expectations and recent cash flows, we are raising our fair value estimate on DaVita to $134 per share from $122.

Sponsor Center